SNTI
Senti Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.23
+0.84%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.22
From 52W high−90.51%
Volume294645.00
Market cap$7.06M
P/E (TTM)—
P/S (TTM)128.4x
Div yield—
Key dataOct 19, 2026
Open
$0.22
From 52W high
−90.51%
Volume
294645.00
Market cap
$7.06M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
32.7
MomentumView details →
1D Return
+0.84%
YTD Return
−77.50%
SummaryUpdated Jun 1, 2026
Senti Biosciences, Inc. (NASDAQ:SNTI) is a gene circuit company founded in 2016 and headquartered in South San Francisco, California. The company went public in May 2021 and operates in the biotechnology sector, focusing on developing advanced cell and gene therapies. Senti has positioned itself at the intersection of synthetic biology and cancer immunotherapy, utilizing engineered gene circuits to create "smart" therapeutic cells that can make complex biological decisions within the human body.
Similar companies
Latest newsMore news →
Brenda Cooperstone resigned as a member and Chair of the Compensation Committee of the Board of Senti Biosciences Holdings, Inc., effective September 23, 2026.25d agoSenti Biosciences Holdings, Inc. amended its Securities Purchase Agreement to authorize the issuance and sale of $2.0 million aggregate principal of Senior Secured Convertible Notes to NSG BioInnovation Fund, L.P. in a third tranche.47d agoSenti Biosciences Holdings, Inc. issued $4.0 million aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 pursuant to an existing securities purchase agreement dated April 27, 2026.61d ago